Status:
NOT_YET_RECRUITING
Microbiome and Polycystic Ovaries
Lead Sponsor:
Sheba Medical Center
Conditions:
Polycystic Ovary Syndrome
Microbial Colonization
Eligibility:
FEMALE
18-42 years
Brief Summary
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder among women in reproductive age with an estimated prevalence of 5% to 19.5%. It is a chronic complex syndrome with psychological ...
Detailed Description
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder among women in reproductive age with an estimated prevalence of 5% to 19.5%. It is a chronic complex syndrome with psychological ...
Eligibility Criteria
Inclusion
- Study group: Untreated women diagnosed with PCOS that are planned for intervention.
- Control group: Women without PCOS visiting the gynecologic outpatient's clinics.
Exclusion
- Endocrine abnormality ( Cushing's syndrome, congenital adrenal hyperplasia, thyroid disorder, hyperprolactinemia and androgen-secreting tumor).
- Premature ovarian failure 2. Active malignancy 3. Participants taking antibiotics/ probiotics, hormonal, vaginal or laxative medicine (in the previous week).
- 4\. Vaginitis/ Pelvic Inflammatory Disease (PID)
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04836910
Start Date
September 1 2025
End Date
March 30 2027
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel, 52621